The population chosen, the “railway research population,” consisted of a sample of Scottish railwaymen, drawn from five of the eight areas in the Scottish Region of British Railways. Only certain occupational grades were studied.
Information was obtained over a period of one year by means of a detailed monthly return of (a) sickness absence data and (b) job changes. Indices of sickness absence were defined. The sickness absence experience of the railway research population was compared with that of other populations. It is a healthier group than the total insured population but differs in some respects from that of London Transport.
The nature of sickness absence within the railway research population was then studied. It was shown in all but one measure used that sickness tends to increase with age, the most important factor being the increase of long episodes. Examination of the frequency distribution of the duration of sickness episodes revealed that sickness absence tends to be taken in terms of weeks off rather than days off.
Analysis of the daily variation in sickness absence showed that the total absence rate increased from Monday to Friday. There was a well defined tendency for sickness to start on Mondays, and in longer episodes an additional tendency to start on Fridays. This was interpreted in terms of morale, both positive and negative.
Marked differences of the same order of magnitude as those due to age were noted in the sickness experience of the various grades, related to both conditions of work and responsibility.
The reasons for job changes were analysed and the grades to which men were transferred were identified. The choice of suitable grades for older workers was discussed.
It was concluded that working conditions might be important factors in the type of sickness absence experienced and that comparisons with other populations might be helpful in this context. More detailed work was also called for on the psychological as well as physical aspects of the work situation for both the individual and the grade.
相似文献Background
Glioblastoma multiforme is the most common malignant primary brain tumor in adults and is associated with poor survival rates. Symptoms often include headaches; nausea and vomiting; and progressive memory, personality, or neurologic deficits. The treatment remains a challenge, and despite the approval of multiple new therapies in the past decade, survival has not improved.Objective
To describe treatment patterns, survival, and healthcare costs of patients with incident glioblastoma in a large US population.Methods
For this population-based study, adult patients (aged ≥18 years) with incident malignant brain neoplasm who had undergone brain surgery between January 1, 2006, and December 31, 2010, were identified in the Truven Health Analytics MarketScan Research Databases. The patients were stratified into 4 cohorts based on the use of temozolomide and/or external beam radiation therapy within 90 days after brain surgery (ie, the index event). Treatment patterns, survival, and healthcare costs were assessed until patient death, disenrollment, or the end-of-study period.Results
A total of 2272 patients met the inclusion criteria; of these, 37% received temozolomide and radiation therapy, 13.8% received radiation alone, 3.9% received temozolomide alone, and 45.3% of patients received neither. The average patient age ranged from 55.3 years to 59.8 years across the study cohorts; between 29.8% and 44% of patients in each cohort were female. The duration of temozolomide use was similar between the temozolomide-only cohort and patients receiving temozolomide with external beam radiation; approximately 76% of patients received temozolomide at least 60 days, dropping to 48.1% and 23% at 180 days and 360 days of follow-up, respectively. The median survival was 456 days, ranging from 331 days in the temozolomide-only cohort to 529 days in the cohort that received neither temozolomide nor external beam radiation. The average total costs in the 6 months postindex were $106,896, from $79,099 for patients who received neither temozolomide nor radiation to $138,767 for those who received both therapies.Conclusion
The survival patterns of patients with glioblastoma seen in this real-world study of current treatments in a clinical setting is similar to the survival rate reported in clinical trials. However, further cost-effectiveness and quality-of-life analyses will be critical to better understand the role of temozolomide therapy in this patient population, considering its considerable cost burden and potential negative impact on survival seen in this study.Glioblastoma multiforme is the most common malignant primary brain tumor in adults, with an estimated incidence of 4.43 per 100,000 person-years in the United States and a median age at presentation of 64 years.1 Glioblastoma multiforme is characterized by seizures; nausea; vomiting; headaches; and progressive memory, personality, or neurologic deficits, as well as treatment resistance.2 The treatment of glioblastoma multiforme is a challenge, and despite the approval of multiple new therapies in the past decade, survival remains poor.Based on a national report on the status of cancer published in 2011 in the Journal of the National Cancer Institute, the 5-year relative survival rates for glioblastoma multiforme among adults between 2000 and 2006 was only 21.3% for patients aged 20 to 39 years, 5.3% for those aged 40 to 64 years, and only 1.1% for patients aged ≥65 years in the United States.1 These national 5-year relative survival rates were slightly better when considering all tumors of the neuroepithelial tissue (65.1%, 26.6%, and 4.6% for the same 3 age-groups, respectively).1The current standard of care for newly diagnosed glioblastoma is derived from a randomized clinical trial published in 2005 and consists of maximal feasible surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide.3 This treatment regimen, known as the Stupp regimen, has resulted in a median survival of 14.6 months in patients receiving temozolomide therapy alone compared with 12.1 months in patients receiving external beam radiation alone.3 The adoption of the Stupp regimen has been credited for improvement in the survival of patients with glioblastoma multiforme from 2005 to 2008 compared with the survival from 2000 to 2003, particularly among younger patients.4,5The US Food and Drug Administration (FDA) approved the use of temozolomide for the treatment of glioblastoma multiforme in March 2005. The FDA also approved carmustine wafers (initially in 1997) and bevacizumab (in 2009, for glioblastoma multiforme that has progressed after initial treatment) for the treatment of glioblastoma multiforme, but neither of these treatments has demonstrated a significant role in the upfront treatment of this disease.6The financial costs associated with the addition of temozolomide are significant and have been well documented, particularly in European and Canadian health systems.7 In the United States, several analyses have underscored the overall costs and burden of out-of-pocket (OOP) costs incurred by patients with glioblastoma multiforme for hospital visits, ancillary care, and drug costs.8,9 The total expenditures in this patient population have also been described in 2007 by Kutikova and colleagues for 653 patients with primary malignant brain tumors and were estimated at $6364 per month compared with $277 for controls.9 These costs were mostly associated with inpatient care and likely reflect patient care before the widespread use of temozolomide.9To our knowledge, no study has comprehensively described the total healthcare costs associated with the treatment of glioblastoma and malignant gliomas in the temozolomide era in the United States. We sought to understand the treatment patterns, survival, and economic burden incurred by patients with glioblastoma in clinical practice in the United States. In this study, we used a large commercial claims database and specifically sought to identify a cohort of patients based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 191.xx codes that most likely represent newly diagnosed glioblastoma to describe patient survival, comorbidities, treatment duration, and healthcare expenditures in the time period after the FDA''s approval of temozolomide.KEY POINTS
- ▸ Glioblastoma multiforme is the most common malignant primary brain tumor in adults, and its survival rates remain poor.
- ▸ The current standard of care consists of surgical resection followed by radiotherapy, with concurrent and adjuvant temozolomide therapy.
- ▸ This is the first study to analyze real-world data related to treatment patterns, costs, and survival trends associated with temozolomide therapy in patients with glioblastoma.
- ▸ Total healthcare costs 6 months postindex were highest ($138,767) per patient receiving temozolomide plus radiation and lowest ($79,099) for those receiving neither.
- ▸ The median survival time was highest (529 days) in patients who received neither temozolomide nor radiation and lowest (331 days) with temozolomide therapy alone.
- ▸ As can be expected, the addition of temozolomide significantly increases the cost of care, and evidence regarding its exact efficacy is limited in this patient population.
- ▸ Future cost-effectiveness and quality-of-life analyses are critical to better understand the role of temozolomide in this patient population.